Prevalence of Multidrug Resistant Pulmonary Tuberculosis in North Bihar

Prevalence of Multidrug Resistant Pulmonary Tuberculosis in North Bihar

Introduction: Multidrug resistant tuberculosis (MDR-TB) is caused by Infection with Mycobacterium tuberculosis which is resistant to both isoniazid (INH) and rifampicin (RIF), with or without any other anti tubercular drug. It is caused by resistant mutant strains due to inadequate treatment an...

Full description

Bibliographic Details
Main Authors:	Sunita Tripathy, Rajesh Kumar, Surya Deo Singh
Format:	Article
Language:	English
Published:	JCDR Research and Publications Private Limited 2015-11-01
Series:	Journal of Clinical and Diagnostic Research
Subjects:	dr tb (drug resistant tuberculosis) inh (isoniazide) irl (intermediate referral laboratory) lpa (line probe assay) programmatic management of drug resistant tb (pmdt)
Online Access:	https://jcdr.net/articles/PDF/6793/14024_CE(Ra1)_F(GH)_PF1(BMAK)_PFA(P)_PF2(PAG).pdf

Similar Items

Drug resistance patterns, treatment outcomes and factors affecting unfavourable treatment outcomes among extensively drug resistant tuberculosis patients in Pakistan; a multicentre record review
by: Muhammad Atif, et al.
Published: (2022-04-01)

Frequency and Factors Associated With Adverse Events Among Multi-Drug Resistant Tuberculosis Patients in Pakistan: A Retrospective Study
by: Muhammad Atif, et al.
Published: (2022-03-01)

Effectiveness of the Novel Anti-TB Bedaquiline against Drug-Resistant TB in Africa: A Systematic Review of the Literature
by: Afsatou Ndama Traoré, et al.
Published: (2022-06-01)

Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
by: Deepika Kalo, et al.
Published: (2015-01-01)

Proportion and trend of primary resistance among Multidrug resistant Tuberculosis patients in Ethiopia
by: Adamu Bayissa, et al.
Published: (2022-05-01)

Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya
by: S. A. Aricha, et al.
Published: (2019-10-01)

Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis
by: Naomee Shareef, et al.
Published: (2023-09-01)

Overview of drug-resistant tuberculosis worldwide
by: Ali A Velayati, et al.
Published: (2016-01-01)

In vitro anti-mycobacterial activity of (E)-N´-(monosubstituted-benzylidene) isonicotinohydrazide derivatives against isoniazid-resistant strains
by: Tatiane S. Coelho, et al.
Published: (2012-02-01)

Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China
by: Fengmin Huo, et al.
Published: (2019-08-01)

Lived experiences of female patients aged 15-49 years undergoing treatment for multi-drug resistant tuberculosis (MDR-TB) in Lira Regional Referral Hospital, Uganda
by: Kizito Omona, et al.
Published: (2024-12-01)

Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia
by: Shiferaw Bekele, et al.
Published: (2018-12-01)

A bioactive implant combining isoniazid with nanohydroxyapatite/polyamide 66 for the treatment of osteoarticular tuberculosis
by: Tianhang Xie, et al.
Published: (2021-11-01)

Drug rash with eosinophilia and systemic symptoms syndrome due to anti-TB medication
by: Dharmesh H Kaswala
Published: (2013-01-01)

Epidemiological profile of multidrug-resistant and extensively drug-resistant Mycobacterium Tubrculosis among Congolese patients
by: Darrel Ornelle Elion Assiana, et al.
Published: (2021-12-01)

Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug
by: Lingaraja Jena, et al.
Published: (2014-01-01)

Tuberculosis: The global killer
by: Bavesh Kana, et al.
Published: (2013-09-01)

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany
by: Barbara Eker, et al.
Published: (2008-11-01)

Can resistance to either isoniazid or rifampicin predict multidrug resistance tuberculosis (MDR-TB)
by: Betty R. Mchaki, et al.
Published: (2023-02-01)

Detection of Second Line Drug Resistance among Drug Resistant Mycobacterium Tuberculosis Isolates in Botswana
by: Tuelo Mogashoa, et al.
Published: (2019-10-01)

Genotypic distribution of multidrug-resistant and extensively drug-resistant tuberculosis in northern Thailand
by: Jaksuwan R, et al.
Published: (2017-06-01)

Whole-Genome Sequencing to Identify Missed Rifampicin and Isoniazid Resistance Among Tuberculosis Isolates—Chennai, India, 2013–2016
by: Sembulingam Tamilzhalagan, et al.
Published: (2021-11-01)

Drug resistance and population structure of M.tuberculosis isolates from prisons and communities in Ethiopia
by: Solomon Ali, et al.
Published: (2016-11-01)

T cell cytokine responses in peripheral blood mononuclear cells from patients with multidrug-resistant tuberculosis following stimulation with proteins purified from Mycobacterium tuberculosis MDR clinical isolates
by: Alireza Hadizadeh Tasbiti, et al.
Published: (2016-01-01)

Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies
by: R Prasad
Published: (2012-01-01)

Multidrug-Resistant Tuberculosis in Europe, 2010–2011
by: Gunar Günther, et al.
Published: (2015-03-01)

Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
by: Fanta Desissa, et al.
Published: (2018-04-01)

Prevalence of Multidrug-Resistant TB Among Smear-Positive Pulmonary TB Patients in Banadir, Somalia: A Multicenter Study
by: Dirie AMH, et al.
Published: (2022-12-01)

Clofazimine for the treatment of tuberculosis
by: Jacob A. M. Stadler, et al.
Published: (2023-02-01)

Social support received by multidrug-resistant tuberculosis patients and related factors: a cross-sectional study in Zhejiang Province, People's Republic of China
by: Chen B, et al.
Published: (2016-06-01)

Universal drug-susceptibility testing of first-line drugs to preserve their efficacy: An essential strategy to defeat tuberculosis
by: Madhur Dev Bhattarai
Published: (2023-12-01)

Variations in rifampicin and isoniazid resistance associated genetic mutations among drug naïve and recurrence cases of pulmonary tuberculosis
by: Saba Kabir, et al.
Published: (2021-02-01)

Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009–2010
by: Vladimir Milanov, et al.
Published: (2015-01-01)

Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa
by: Navisha Dookie, et al.
Published: (2016-10-01)

Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing
by: Jun Chen, et al.
Published: (2017-04-01)

Use of rapid molecular test for multidrug-resistant tuberculosis detection among relapse cases in Cote d'Ivoire
by: K N′guessan, et al.
Published: (2014-01-01)

Spermine enhances the activity of anti-tuberculosis drugs
by: Carine Sao Emani, et al.
Published: (2024-01-01)

Gene mutation patterns of Mycobacterium tuberculosis complex and associated factors among suspected multidrug-resistant tuberculosis patients in Osun State, South-West, Nigeria
by: Onaiwu T. Ohiengbomwan, et al.
Published: (2023-11-01)

Clinical features, resistance patterns and treatment outcomes of drug-resistant extra-pulmonary tuberculosis: A scoping review
by: Emmanuel Miiro, et al.
Published: (2023-12-01)

Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study
by: Joanitah Nalunjogi, et al.
Published: (2023-05-01)